Cargando…

Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS

OBJECTIVE: To analyze the changes induced by ocrelizumab in blood immune cells of patients with primary progressive MS (PPMS). METHODS: In this multicenter prospective study including 53 patients with PPMS who initiated ocrelizumab treatment, we determined effector, memory, and regulatory cells by f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernández-Velasco, José I., Kuhle, Jens, Monreal, Enric, Meca-Lallana, Virginia, Meca-Lallana, José, Izquierdo, Guillermo, Gascón-Giménez, Francisco, Sainz de la Maza, Susana, Walo-Delgado, Paulette E., Maceski, Aleksandra, Rodríguez-Martín, Eulalia, Roldán, Ernesto, Villarrubia, Noelia, Saiz, Albert, Blanco, Yolanda, Sánchez, Pedro, Carreón-Guarnizo, Ester, Aladro, Yolanda, Brieva, Luis, Íñiguez, Cristina, González-Suárez, Inés, Rodríguez de Antonio, Luis A., Masjuan, Jaime, Costa-Frossard, Lucienne, Villar, Luisa M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862094/ https://www.ncbi.nlm.nih.gov/pubmed/33408167 http://dx.doi.org/10.1212/NXI.0000000000000940

Ejemplares similares

Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology
por: Fernández-Velasco, José I., et al.
Publicado: (2022)

Spasticity in multiple sclerosis and role of glatiramer acetate treatment
por: Meca-Lallana, Jose Eustasio, et al.
Publicado: (2015)

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab
por: Walo-Delgado, Paulette Esperanza, et al.
Publicado: (2021)

Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine
por: Rodero-Romero, Alexander, et al.
Publicado: (2023)

Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment
por: Walo-Delgado, Paulette Esperanza, et al.
Publicado: (2021)

XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)
por: Fernández, Óscar, et al.
Publicado: (2023)

XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)
por: Fernández, Óscar, et al.
Publicado: (2023)

Short- and Long-Term Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies
por: Sainz de la Maza, Susana, et al.
Publicado: (2023)

Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome
por: Monreal, Enric, et al.
Publicado: (2021)

Assessing fatigue in multiple sclerosis: Psychometric properties of the five-item Modified Fatigue Impact Scale (MFIS-5)
por: Meca-Lallana, Virginia, et al.
Publicado: (2019)

Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder
por: Lopez-Soley, Elisabet, et al.
Publicado: (2022)

Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients’ Perspective: An Observational Cross-Sectional Study
por: Meca-Lallana, José E., et al.
Publicado: (2022)

Establishing the best combination of the kappa free light chain index and oligoclonal bands for an accurate diagnosis of multiple sclerosis
por: Monreal, Enric, et al.
Publicado: (2023)

Cognitive Dysfunctions and Assessments in Multiple Sclerosis
por: Oreja-Guevara, Celia, et al.
Publicado: (2019)

Quantifying the patient´s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire
por: Meca-Lallana, José E., et al.
Publicado: (2021)

Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder
por: Meca-Lallana, Jose E, et al.
Publicado: (2021)

Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing–Remitting Multiple Sclerosis: Quantifying the Patient’s Perspective
por: Meca-Lallana, José, et al.
Publicado: (2020)

High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study
por: Monreal, Enric, et al.
Publicado: (2020)

Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
por: Sánchez-de la Rosa, Rainel, et al.
Publicado: (2015)

COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
por: Meca-Lallana, Virginia, et al.
Publicado: (2020)

Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
por: Aguirre, Clara, et al.
Publicado: (2020)

Disability and Fatigue in Multiple Sclerosis: Can Rehabilitation Improve Them through a Structured Retraining Program?
por: Arriaza, María José, et al.
Publicado: (2022)

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
por: Barrero, Francisco, et al.
Publicado: (2020)

Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients
por: Medina, Silvia, et al.
Publicado: (2019)

Information-Seeking Strategies of People with Multiple Sclerosis in Spain: The INFOSEEK-MS Study
por: Higueras, Yolanda, et al.
Publicado: (2022)

Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis
por: Picón, Carmen, et al.
Publicado: (2021)

Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry
por: Meca-Lallana, J. E., et al.
Publicado: (2021)

Consensus on early detection of disease progression in patients with multiple sclerosis
por: Meca-Lallana, José E., et al.
Publicado: (2022)

Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus
por: Sepúlveda, Maria, et al.
Publicado: (2016)

Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: safety algorithm()
por: Valero-López, G., et al.
Publicado: (2020)

Erratum to ‘‘Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: Safety algorithm’’ [Neurologia. 2020;35(6):357–362]()
por: Valero-López, G., et al.
Publicado: (2020)

Fe de errores a “Tratamiento inmunosupresor en pulsos en esclerosis múltiple durante el desescalado de la epidemia por SARS-CoV-2. Algoritmo de seguridad” [Neurologia. 2020;35(6):357–362]
por: Valero-López, G., et al.
Publicado: (2020)

Tratamiento inmunosupresor en pulsos en esclerosis múltiple durante el desescalado de la epidemia por SARS-CoV-2. Algoritmo de seguridad
por: Valero-López, G., et al.
Publicado: (2020)

Perception of stigma in patients with primary progressive multiple sclerosis
por: Pérez-Miralles, Francisco, et al.
Publicado: (2019)

Establishment of a safety protocol for the administration of treatments in multiple sclerosis during the SARS-CoV-2 pandemic
por: Meca-Lallana, Virginia, et al.
Publicado: (2020)

Deciphering Multiple Sclerosis Progression
por: Meca-Lallana, Virginia, et al.
Publicado: (2021)

Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis
por: Pérez‐Miralles, Francisco Carlos, et al.
Publicado: (2021)

Cognitive impairment in multiple sclerosis: diagnosis and monitoring
por: Meca-Lallana, Virginia, et al.
Publicado: (2021)

The Impact of Immunosuppression and Autoimmune Disease on Severe Outcomes in Patients Hospitalized with COVID-19
por: Monreal, Enric, et al.
Publicado: (2020)

Expert-Agreed Practical Recommendations on the Use of Cladribine
por: Meca-Lallana, Virginia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8djctsru1veqimmq7j3lns1bh0